Sameer S. Walunj

Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

R. C. Gupta, Sameer S. Walunj, Ranjeet K. Tokala et al. · Current Drug Targets · 2009 · 106 citations

Immunogenic and antigenic properties of recombinant soluble glycoprotein of rabies virus

Praveen K. Gupta, Sameer Sharma, Sameer S. Walunj et al. · Veterinary Microbiology · 2005 · 34 citations

Vaccination, Viral Pathogenesis, Immunology +5

Cinnamomum zeylanicum extract inhibits proinflammatory cytokine TNF: in vitro and in vivo studies

Kalpana Joshi, Shyam Awte, Payal Bhatnagar et al. · Research in Pharmaceutical Biotechnology · 2010 · 32 citations · Full text

Immunology, Inflammatory Arthritis, Oxidative Stress +17

Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure–Activity Relationship and Preclinical Characterization

Neelima Sinha, Navnath P. Karche, Mahip Verma et al. · Journal of Medicinal Chemistry · 2019 · 25 citations · Full text

A DNA vaccine that encodes rabies virus glycoprotein lacking transmembrane domain enhances antibody response but not protection.

Praveen K. Gupta, Shaifali Sharma, Sameer S. Walunj et al. · PubMed · 2006 · 10 citations

Vaccination, Vaccinology, Cross-protection +15